A Phase 2 interventional study of SyB L-0501 and Rituximab in Non-Hodgkin's Lymphoma, Lymphoma, Large Cell and Diffuse, Mantle Cell Lymphoma, Lymphoma, sponsored by SymBio Pharmaceuticals. Completed at 25 sites in 2 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-04.
Sponsored by SymBio Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing bendamustine in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. bendamustine · Lymphoma, Non-Hodgkin.
Among the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 10 that started in 2010, is one of 19 in phase 2, and was the 18th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 5
First in 2003; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 40 interventional studies. Of the 34 that completed or were terminated, 18 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
SymBio Pharmaceuticals is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
SymBio Pharmaceuticals has 4 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Primary Objective is to determine the efficacy, as measured by overall response rate on the basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m\^2/day on day2 and 3 in combination with rituximab at 375 mg/m\^2 on day 1 of each 21-day cycle in patients with relapsed/refractory diffuse large B-cell lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SyB L-0501 · Drug: Rituximab
The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule. SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.
Also known as: Bendamustine hydrochloride
The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites. For the criteria for CR, See Outcome measure 2 description. The criteria for PR is as below. Nodal Masses: more than 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: more than 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified
Time frame: up to 30 weeks
The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
The criteria for CR is as below Nodal Masses: 1. fluorodeoxy glucose (FDG)-avid or positron emission tomography (PET) positive prior to therapy; mass of any size permitted if PET negative 2. Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT) Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative
Time frame: up to 30 weeks
Progression Free Survival (PFS)
PFS = day of the first PFS event - day of start of study treatment + 1 The definitions of PFS event are as below. 1. PD according to overall response on the basis of Revised Response Criteria for Malignant Lymphoma PD: Any new lesion or increase by ≥50% of previously involved sites from nadir. Nodal masses; Appearance of a new lesion(s) \>1.5 cm in any axis, ≥50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis. Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Spleen, Liver; ≥50% increase from nadir in the SPD of any previous lesions. Bone marrow; New or recurrent involvement 2. Disease progression during treatment period 3. Disease progression during follow up period 4. Start of treatment of new lesion 5. Occurrence of other multiple malignant tumors 6. Death
Time frame: up to 30 weeks
Number of Subjects With Adverse Event
Time frame: up to 30 weeks
Number of Adverse Events
Time frame: up to 30 weeks
Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild grade 2 : moderate grade 3 : severe grade 4 : life threatening or disabling grade 5 : death related to adverse event
Time frame: up to 30 weeks
Number of Subjects With Grade ≥3 Physical Examination Finding
Time frame: up to 30 weeks
Concomitant Medication Usage
Time frame: up to 30 weeks
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea
Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
| Milestone | SyB L-0501 |
|---|---|
| Started | 59 |
| Completed | 17 |
| Not completed | 42 |
CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites. For the criteria for CR, See Outcome measure 2 description. The criteria for PR is as below. Nodal Masses: more than 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: more than 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified
| Percentage of Participants | SyB L-0501 |
|---|---|
| The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma | 62.7 (49.1 to 75.0) |
The criteria for CR is as below Nodal Masses: 1. fluorodeoxy glucose (FDG)-avid or positron emission tomography (PET) positive prior to therapy; mass of any size permitted if PET negative 2. Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT) Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative
| Percentage of participants | SyB L-0501 |
|---|---|
| The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma | 37.3 (25.0 to 50.9) |
PFS = day of the first PFS event - day of start of study treatment + 1 The definitions of PFS event are as below. 1. PD according to overall response on the basis of Revised Response Criteria for Malignant Lymphoma PD: Any new lesion or increase by ≥50% of previously involved sites from nadir. Nodal masses; Appearance of a new lesion(s) \>1.5 cm in any axis, ≥50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis. Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Spleen, Liver; ≥50% increase from nadir in the SPD of any previous lesions. Bone marrow; New or recurrent involvement 2. Disease progression during treatment period 3. Disease progression during follow up period 4. Start of treatment of new lesion 5. Occurrence of other multiple malignant tumors 6. Death
| Days | SyB L-0501 |
|---|---|
| Progression Free Survival (PFS) | 200.0 (109.0 to 410.0) |
| Participants | SyB L-0501 |
|---|---|
| Subjects with adverse event | 59 |
| Subjects with serious adverse event | 14 |
| Events | SyB L-0501 |
|---|---|
| Adverse events | 1848 |
| Serious adverse events | 23 |
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild grade 2 : moderate grade 3 : severe grade 4 : life threatening or disabling grade 5 : death related to adverse event
| Participants | SyB L-0501 |
|---|---|
| Subjects with grade 3 abnormality | 2 |
| Subjects with grade 4 abnormality | 54 |
| Participants | SyB L-0501 |
|---|---|
| Subjects with grade 3 Physical Findings | 1 |
| Subjects with grade 4 Physical Findings | 22 |
| Participants | SyB L-0501 |
|---|---|
| concomitant medications for adverse events | 58 |
| concomitant medications for complications | 50 |
| concomitant medications for supportive therapy | 59 |
| concomitant medications for other reasons | 59 |
| ng/mL | SyB L-0501 |
|---|---|
| The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan | 8365.82 ± 3522.73 |
| hour | SyB L-0501 |
|---|---|
| The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan | 1.0 ± 0.0 |
| ng・h/mL | SyB L-0501 |
|---|---|
| The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan | 10394.39 ± 5368.77 |
| hour | SyB L-0501 |
|---|---|
| The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan | 0.39 ± 0.1 |
| ng/mL | SyB L-0501 |
|---|---|
| The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea | 8095.99 ± 4339.74 |
| hour | SyB L-0501 |
|---|---|
| The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea | 0.9 ± 0.3 |
| ng・h/mL | SyB L-0501 |
|---|---|
| The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea | 9218.56 ± 6696.81 |
| hour | SyB L-0501 |
|---|---|
| The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea | 0.48 ± 0.18 |
Collected over up to 30 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SyB L-0501 | — | 14/59 (23.7%) | 59/59 (100%) |
| Event | SyB L-0501 |
|---|---|
| Cytomegalovirus infectionInfections and infestations | 3/59 |
| PneumoniaInfections and infestations | 3/59 |
| ConstipationGastrointestinal disorders | 2/59 |
| AstheniaGeneral disorders | 2/59 |
| NeutropeniaBlood and lymphatic system disorders | 1/59 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/59 |
| DiarrhoeaGastrointestinal disorders | 1/59 |
| DeathGeneral disorders | 1/59 |
| Mucosal inflammationGeneral disorders | 1/59 |
| InfectionInfections and infestations | 1/59 |
| Event | SyB L-0501 |
|---|---|
| CD4 lymphocytes decreasedInvestigations | 41/59 |
| White blood cell count decreasedInvestigations | 37/59 |
| Neutrophil count decreasedInvestigations | 34/59 |
| Lymphocyte count decreasedInvestigations | 33/59 |
| AnaemiaBlood and lymphatic system disorders | 30/59 |
| ConstipationGastrointestinal disorders | 29/59 |
| White blood cell count increasedInvestigations | 27/59 |
| Blood immunoglobulin G decreasedInvestigations | 26/59 |
| Platelet count decreasedInvestigations | 26/59 |
| Blood immunoglobulin M decreasedInvestigations | 25/59 |
| Age Continuous(Year) | SyB L-0501 |
|---|---|
| Mean | 64.2 ± 9.2 |
| Age, Customized(Percentage of participants) | SyB L-0501 |
|---|---|
| 20-29 years | 0.0 |
| 30-39 years | 1.7 |
| 40-49 years | 8.5 |
| 50-59 years | 16.9 |
| 60-69 years | 39.0 |
| 70-75 years | 33.9 |
| Age, Customized(Percentage of participants) | SyB L-0501 |
|---|---|
| <65 years | 37.3 |
| ≥65 years | 62.7 |
| Sex/Gender, Customized(percentage of participants) | SyB L-0501 |
|---|---|
| Male | 42.4 |
| Female | 57.6 |
| Diagnosis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma(percentage of participants) | SyB L-0501 |
|---|---|
| Number | 100.0 |
| Clinical Stage (Ann Arbor staging)(Percentage of participants) | SyB L-0501 |
|---|---|
| Stage I | 5.1 |
| Stage I-E | 3.4 |
| Stage II | 27.1 |
| Stage II-E | 3.4 |
| Stage III | 25.4 |
| Stage III-S | 6.8 |
| Stage III-E | 3.4 |
| Stage III-SE | 0.0 |
| Stage IV | 25.4 |
| Unknown | 0.0 |
| Systemic symptoms (B symptoms) (Ann Arbor staging)(Percentage of participants) | SyB L-0501 |
|---|---|
| Asymptomatic | 86.4 |
| Symptomatic | 13.6 |
| Unknown | 0.0 |
| Medical history of diffuse large B-cell lymphoma (DLBCL)(Percentage of participants) | SyB L-0501 |
|---|---|
| No | 40.7 |
| Yes | 59.3 |
20 further baseline measures are reported on the registry.
The record gives a start of Apr 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bendamustine · Rituximab